Article info
Poster Presentations
Rheumatoid arthritis - anti-TNF therapy
THU0149 The 54-Week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, To Infliximab Reference Product in Patients with Rheumatoid Arthritis
Citation
THU0149 The 54-Week Results of Interferon-γ Release Assay in A Phase III Study Comparing SB2, An Infliximab Biosimilar, To Infliximab Reference Product in Patients with Rheumatoid Arthritis
Publication history
- First published July 15, 2016.
Online issue publication
February 10, 2017
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2016, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions